Press release
Inflammatory Bowel Disease (IBD) Treatment Market is Expected to Reach $15.5 bn by 2027
The Inflammatory Bowel Disease (IBD) treatment market share was US$ 11.38 Bn in the year 2018. The market is anticipated to grow at a rate of 3.94%, through the forecast period to reach US$ 15.5 Bn by the year 2027.Inflammatory Bowel Disease (IBD) usually denotes disorders characterized by the inflammation in the digestive system. Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome are two different disorders that are often confused with each other. IBS is neither characterized by inflammation nor causes damage to the bowel tissues.
IBD is categorized into Crohn's disease (CD) & Ulcerative Colitis (UC). CD can affect the digestive tract right from the mouth to the rectum. CD appears in patches, can penetrate and affect multiple layers and organs associated with the digestive tract. Conversely, UC is continuous, limited to inflammation of colon and rectum, and inner lining of the colon. IBD is debilitating with symptoms such as weight loss, fatigue, abdominal pain, and diarrhoea. Adverse conditions can lead to mortality too. There are no defined causes for the occurrence of IBD, yet it can be attributed to defects in the immune system or can be hereditary.
The overall worldwide incidence rates are about 380-400 cases per 100,000 individuals. In the US alone, more than 3.2 million adults suffer from IBD, while in the EU, the affected population is about 2.1 million. The incidence of IBD in Asia is the lowest with rates of about 5 per 100,000 individuals. Individuals aged over 45 are more susceptible to acquire IBD. Among the two types of IBD, UC is more common with an incidence rate of about 1-25.5 cases per 100,000 while that of CD is about 0.2-18 cases per 10,000 individuals. IBD does not have a disparity amongst the male and female populations across the globe, nevertheless, UC more commonly occurs in the US male population than in the female. With the number of incidences of ulcerative colitis, the particular segment is rapidly increasing with more treatment modalities under development. Also, the prevalence is more in US and EU countries, hence, the North American region followed by the EU region contributes more to the growth of the IBD treatment market. Besides, the presence of major market players and the healthcare infrastructure is expected to further fuel the market growth. Asia Pacific region, though a less contributive region, is anticipated to increase its contribution towards the growth of the market owing to change in lifestyle and eating habits.
According to the study conducted by the Crohn's & Colitis Foundation for ten years from 2007-2016 confirmed that the average treatment costs incurred for IBD had increased tremendously over the past 5 years. Further, it is noticed the current average treatment cost is about $26500. This is considered as one of the major restraints that will hamper the growth of the market. Also, the diagnosis of IBD is difficult due to it having more common symptoms associated with other similar diseases. Besides, the awareness of IBD was also poor, however, initiatives from government and NGOs are seeding the knowledge of IBD and its symptoms among people which is an encouraging sign for the growth of the market.
The current treatment regimens of IBD consists of injectables and oral therapies wherein injectables are preferred due to its efficacy. TNF inhibitors which are expected to subside the inflammation is more preferred injectable therapeutic form and dominated the market share. Nevertheless, the companies are focusing to develop an efficacious oral therapy owing to the ease of use. Aminosalicylates which are used for treating mild or moderate IBD dominated the oral segment. In recent years, the development of biosimilars is underway, which could offer a cost-effective treatment contributing to market growth.
Optima Insights provides the latest update on the industry trends, products & pipeline analysis with country, regional and global revenue forecast till the year 2027. The analysis of the market is segmented into Type (Crohn's Disease & Ulcerative Colitis); Administration Injectables (TNF inhibitors, Interleukin inhibitors, Anti-integrin) & Oral (Aminosalicylates, Corticosteroids, JAK inhibitors); Distribution Channel (Hospital, Retail, Online) & Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
Request for Sample Pages @ https://www.optimainsights.org/sample-request/210-inflammatory-bowel-disease-treatment-market
Major companies which develop drugs for Inflammatory Bowel Disease Market include Johnson & Johnson, Pfizer, Takeda Pharmaceuticals, Sanofi, Abbott, Biocon, F. Hoffman La Roche, Quest Medicals, Novartis, Mylan, AbbVie Inc, Celltrion, Celgene, Cosmo Pharmaceuticals, Innovate Biopharmaceuticals, Gilead, UCB Pharma, and many more
Research Scope
o Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
o Provides a Comparative Analysis of Key Marketed and Pipeline Products.
o Provides Key Information on Players involved.
o Provides a Complete Overview of Market Segments and the Regional Outlook.
o Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
History of the Inflammatory Bowel Disease, 2015 to 2019
Forecast of the Inflammatory Bowel Disease Growth till the year 2027
The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Inflammatory Bowel Disease (IBD) Market
Analysis of potential growth segments which will drive the market
Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/210-inflammatory-bowel-disease-treatment-market
Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: sales@optimainsights.org
https://www.optimainsights.org
About Us
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.Contact
Optima Insights
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)
Email: sales@optimainsights.org
https://www.optimainsights.org
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Inflammatory Bowel Disease (IBD) Treatment Market is Expected to Reach $15.5 bn by 2027 here
News-ID: 1927284 • Views: …
More Releases from Optima insights Pvt Ltd
Endometriosis Treatment Market is Expected to Reach $3.43 bn by 2027
The Endometriosis Treatment Market was valued at US $2.64 billion in the year 2019 and is estimated to reach US $3.43 billion by 2027, at a CAGR of 3.36%.
The growth of tissue outside the uterus similar to lining of uterus (endometrium) refers to Endometriosis. Areas of endometrial tissue growth often occur in ovaries, fallopian tubes, peritoneum and outer surfaces of bladder, uterus, intestines, and rectum and rarely spread beyond pelvic…
Polycystic Ovarian Syndrome (PCOS) Treatment Market is Expected to Reach $5.59 b …
The Polycystic Ovarian Syndrome (PCOS) Treatment Market was valued at US $3.74 billion in the year 2019 and is estimated to reach US $5.59 billion by 2027, at a CAGR of 5.18%.
Polycystic Ovarian Syndrome (PCOS), also referred to as Stein-Leventhal syndrome is a hormonal disorder characterized by enlarged ovaries and formation of numerous small cysts (fluid-filled sacs) on the outer edges of the ovaries. Symptoms of PCOS include irregular periods,…
Veterinary Vaccines Market is Expected to Reach $13.51 bn by 2027
The Veterinary Vaccines Market was valued at US $7.91 billion in the year 2018 and is estimated to reach US $13.51 billion by 2027, at a CAGR of 6.13%.
Generally, vaccines are effective in preventing infectious diseases. Veterinary vaccines especially reduce the burden of the disease in animals and also helps in preventing several zoonotic diseases also. There are four types of veterinary vaccines available depending on preparation type, they are…
Animal Feed Additives Market is Expected to Reach $47.75 bn by 2026
The Animal Feed Additives Market was valued at US$35.82 billion in the year 2018 and is estimated to reach US$47.75 billion by 2026, at a CAGR of 3.66%.
Feed additives are substances that enhance the nutritional efficiency of animals. The use of additives in veterinary feed is practiced from the early 1960s, especially, antibiotics are an integral part of veterinary health. Besides, several feed additives including probiotics, amino acids, vitamins and…
More Releases for IBD
Canada Inflammatory Bowel Disease (IBD) Market Size & Growth Analysis Report, 20 …
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease,…
Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Visiongain has published a new report on Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios.
Global Inflammatory Bowel Disease (IBD) drugs market was valued at US$ US$xx…
US Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Forecast 20 …
The US IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. The factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per…
France Inflammatory Bowel Disease (IBD) Therapeutics Market Size, Growth and For …
France IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.6% during the forecast period. The growing IBD patient population is one of the major driving forces for the growth of the market in the country. According to the National Institutes of, Health, the total number of cases associated with Crohn's disease in France were registered to be around 72,522 in 2017. This signifies the opportunity…
Global Inflammatory Bowel Disease (IBD) Therapeutics Market, Share, Trends & For …
The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and…
Canada Inflammatory Bowel Disease (IBD) Market Share, Size & Forecast to 2025
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn's disease,…
